《道德经》有言："胜人者有力，自胜者强。" 富国基金在权益投研体系建设方面持续精进，不断前行 投资时间网、标点财经研究员 齐文健 随着我国居民财富持续增长，资产配置需求日渐增加，公募基金成为其中重要一环，可供投资者选择的产品愈发丰富。主动权益类基金、被动指数型基 金、纯债型基金、FOF、QDII……不同功能属性的产品整齐排列在"理财货架"上。 但是，要选择哪一款？投资者需要深思熟虑。不难看出，近年来，围绕产品业绩的关注度越来越高，投资者不再只满足于产品短期业绩，中长期成绩被反 复考察。 近日，标点财经研究院根据Wind、银河证券、基金季报等多方数据，通过对中国基金业过去7年、5年、3年等海量数据进行统计研究，重磅推出《中国基 金业马拉松大师荟·2025》。 在全市场上万只产品中，管理规模稳居业内第一梯队的富国基金旗下有哪些中长期业绩稳居同类前列的权益产品？ 权益投资现硬核实力 伴随资管行业快速发展，投资者购买理财产品并非难题。但在权益市场波动、优质资产荒、银行理财产品破净等因素叠加下，投资者的投资难度又居高不 下。投资者对于能够提供稳健中长期业绩的产品需求可谓十分迫切。 投资时间网、标点财经研究员注意到，以权 ...

Core Viewpoint - The article discusses the significant transformation in China's innovative drug sector, highlighting the emergence of a "DeepSeek" moment driven by improved recognition of the technology attributes of innovative drugs and a stabilizing policy environment [1][55][57]. Group 1: Industry Background - The narrative of China's innovative drug industry has evolved dramatically from a low starting point, with a focus on the systemic operational models of leading companies [2][6]. - The shift from pursuing "Chinese new" to "global new" in innovative drugs began around 2018, emphasizing the need for global competitiveness [28][29]. Group 2: Investment Strategy - The investment framework developed by the fund manager emphasizes the importance of selecting companies that can achieve global competitiveness, focusing on speed, optimization, and innovation [6][30]. - The ideal investment stage is identified as clinical phase II, where early data signals can provide opportunities for entry [9][34]. Group 3: Market Dynamics - The current market performance of innovative drugs is attributed to two main factors: enhanced recognition of their technological attributes and a more stable policy environment [55][57]. - The article notes that the number of global INDs and clinical trials from China has significantly increased, indicating a robust supply side [63]. Group 4: Future Outlook - The article suggests that the innovative drug sector is at a critical turning point, with international interest in Chinese innovative drug assets growing [65][66]. - The potential for growth in the innovative drug market remains substantial, particularly as companies begin to achieve revenue and profit growth [60][61].

例如，大成基金自5月20日起对大成竞争优势混合开通同一基金不同份额类别间的转换业务。自5月6日起，富国基 金对富国沪港深价值精选灵活配置混合、富国医药创新股票、富国国家安全主题混合、富国品质生活混合、富国 新机遇灵活配置混合、富国核心优势混合、富国天瑞强势地区精选混合7只基金开通同一基金不同类别基金份额之 间的转换业务。上述基金均设有A类份额和C类份额。 此外，今年以来，还有长城基金、鹏华基金、广发基金、华宝基金、摩根资产管理、兴证全球基金、宏利基金、 蜂巢基金等陆续公告对旗下部分产品开通这一业务。 在业内人士来看，基金公司提供转换服务，主要是为了适应机构投资者投资需求的变化。对于资金量较大的投资 者而言，原先持有C份额，但预计需较长时间回本，转换为A份额可节省长期持有成本。有的投资者原先持有A份 额，但因资金用途改变需赎回，面临较高赎回费时，转换为C份额则更为合适。 同一基金不同份额之间的灵活转换，为投资者提供了更多选择，使其能够根据自身投资需求和市场情况做出相应 调整。例如，当某一类基金份额表现不佳时，投资者可及时将其转换为另一类表现较好的份额，从而降低损失、 提高收益。此外，对于直销投资者而言，转换成本 ...

近年来，为满足投资者的不同投资策略、不同持有期限的需求，公募基金份额越来越"五花八门"，C份 额、D份额等日益常见。基金不同份额合并运作，在投资策略和范围上并无差异，但费率、销售渠道、 申购门槛等方面并不相同，通常情况下，同一基金的不同份额之间无法相互转换。中国证券报记者关注 到，近日多家基金公司公告开通旗下同一基金不同份额类别转换业务。 据了解，此举主要是为了满足投资者在不同投资策略之间切换的需求，尤其是机构投资者持有期限变化 的需求，提升投资者资金使用的灵活性。 ● 本报记者 张舒琳 多只公募基金公告 近年来，越来越多的基金增设C份额，由于收费形式更适合短期投资，C份额备受来自互联网销售渠道 的个人投资者的欢迎，还有一些基金增设了D份额、I份额等。基金的不同份额虽然合并运作，但在费 率、销售渠道、申购门槛等方面存在差异。 例如，A份额通常是申购时一次性收取申购费，持有基金需要超过一定时间才能免赎回费，有利于持有 时间较长的投资者；C份额不收取申购费，只收取销售服务费，按日计提，持有较短时间即可免赎回 费，因此更适合短期投资者；D份额通常是针对直销渠道的机构投资者而设置，方便机构大额资金进 出。 中国证券报 ...

Core Viewpoint - Tencent Licai Tong collaborates with various fund companies, including Fuguo Fund, to launch the "Million Investment Experience" activity starting from May 15, 2025, aimed at providing a safe and realistic investment learning experience for investors [1][2] Group 1: Activity Highlights - The activity features zero entry barriers, allowing participation without the need for fund account opening, subscription, or any capital flow changes, thus eliminating actual financial risks [1][2] - Participants can earn real returns, with a maximum potential gain of 10,000 yuan, and the experience simulates a 30 trading day investment cycle with real-time market data [1][2] - Three representative fund products are selected to cater to different investor needs, including Fuguo Shanghai Gold ETF, Fuguo Tianli Growth Bond, and Fuguo Pharmaceutical Innovation Stock, each representing different asset allocation tools [1][2] Group 2: Innovative Features - The activity breaks traditional investment models by allowing investors to experience a complete investment cycle with real market data, enhancing the learning experience [2] - A tiered structure for investment amounts is established, with a maximum potential return of 10,000 yuan, and a profit protection mechanism ensures that participants can withdraw positive returns even in case of losses [2] - Participants can easily join the activity through WeChat by following the Fuguo Fund official account, making it accessible for more investors to engage with professional asset management services [2]